1. Chemotherapeutic Prevention and Treatment of COVID-19 Myocardial Injury with Thalidomide and Celecoxib.
- Author
-
Masato Hada, Rashid, Abid, Abaka, Abdulazeez M., Akram, Muhammad, Laila, Umme, Zainab, Rida, Iftikhar, Momina, Saleem, Sundus, Khalil, Muhammad Talha, Mbaye, El Hadji Seydou, Parmar, Pragnesh, and Elbossaty, Walaa Fikry
- Subjects
MYOCARDIAL injury ,COVID-19 treatment ,MYOCARDIAL infarction ,THALIDOMIDE ,CELECOXIB ,THYROID crisis - Abstract
Older people and patients with an underlying disorder are more susceptible to COVID-19 infection, which can be exacerbated by a cytokine storm or hypercytokinemia. Myocardial injury is the most serious and life-threatening complication may be a major cause of death as a result of infection with Covid 19. Studies have shown that patients who do not suffer from acute myocardial infarction (AMI) injury recover by a large percentage compared to those infected. Galectin-3 acting a significant pathophysiological role in inflammatory responses, atherosclerosis, and diabetes. The transcription factor NF-κB regulates inflammatory responses and expresses more than 400 genes associated with a variety of processes, including all biochemical and biophysical process. Thalidomide act as an immunomodulatory agent that, in combination with the COX-2 inhibitor celecoxib, strongly suppresses activated NF-κB. The combination improves the prognosis of COVID-19 patients with myocardial injury. [ABSTRACT FROM AUTHOR]
- Published
- 2023